Related Experiment Videos
Saliva carbamazepine levels in children before and during multiple dosing
Insights
Carbamazepine (CBZ) therapy in children shows increased clearance and reduced half-life over five weeks. Saliva CBZ levels were lower than predicted, indicating altered pharmacokinetics during treatment.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Clinical Pharmacokinetics
Background:
- Carbamazepine (CBZ) is a widely used antiepileptic drug.
- Understanding CBZ pharmacokinetics in children is crucial for effective dosing.
- Saliva is a non-invasive matrix for monitoring drug concentrations.
Purpose of the Study:
- To determine saliva carbamazepine (CBZ) pharmacokinetics in children aged 7-11 years.
- To assess changes in CBZ pharmacokinetics after 5 weeks of therapy.
- To compare predicted CBZ concentrations with actual steady-state levels.
Main Methods:
- Six children (7-11 years) received a single oral dose of CBZ (14.7 +/- 2.3 mg/kg).
- Saliva samples were collected over 36 hours post-dose at baseline and after 5 weeks of continuous therapy.
- Pharmacokinetic parameters including clearance, half-life, and volume of distribution were calculated.
Main Results:
- Saliva CBZ clearance significantly increased from 142 +/- 28 to 402 +/- 79 ml/h/kg (P < 0.001).
- Mean saliva CBZ half-life significantly decreased from 23.6 +/- 5.3 to 8.0 +/- 2.3 h (P < 0.005).
- Apparent volume of distribution remained similar; steady-state CBZ concentrations were <40% of predicted values.
Conclusions:
- CBZ pharmacokinetics undergo significant changes during the initial 5 weeks of therapy in children.
- Increased clearance and reduced half-life suggest enhanced drug elimination over time.
- Current dosing predictions may overestimate CBZ levels in children receiving long-term therapy.
Abstract:
1 Saliva carbamazepine (CBZ) pharmacokinetics were determined in six children aged 7-11 years at the start and after 5 weeks of CBZ therapy. 2 A single oral dose of CBZ, 14.7 +/- 2.3 mg kg -1, was administered and mixed saliva was collected at intervals during the next 36 h. CBZ therapy was then continued using the same total daily dose divided into two equal doses. After 5 weeks of therapy saliva samples were collected once more as on day 1. 3 The mean (+/- s.d.) saliva CBZ clearance increased over the study period from 142 +/- 28 to 402 +/- 79 ml h -1 kg -1 (P less than 0.001) and the mean half-life decreased from 23.6 +/- 5.3 to 8.0 +/- 2.3 h (P less than 0.005). The mean apparent volume of distribution after the first dose, 4.72 +/- 0.84 1 kg -1, was similar to that after 5 weeks treatment, 4.66 +/- 1.68 1 kg -1. 4 The mean saliva steady-state CBZ concentrations after 5 weeks therapy were less than 40% of those predicted from the single dose kinetic parameters.